Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 45

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 45
---
 the same period in previous year Consulting and Professional fees expenditure were $95,539. During the period ended 2024 research and development expenses amounted to $32,500 constituting the second largest expense recognized during that quarter.

| 36 |

Other Income

For the three months ended June 30 2025, the Company reported a net other expense of $(126,526) whereas in the same period ended 2024 the Company reported the net other expense of $(22,154). Net other expense for the quarter ended 2025 was primarily driven by the recognition of a Derivative Loss of $(89,259). For the quarter ended June 30, 2025 the Company also recognized higher interest and amortization expenses as compared to the quarter ended 2024.

Net Loss

The Company recognized an Operating Loss of $ 40,759 during the three months ended June 30, 2025 whereas the Company recognized an Operating Loss of $ 107,966 for the same period ended 2024. The reduction in operating loss is primarily attributable to a reduction in all expense categories other than General and Administrative expenses and rent incurred during the period ended 2024 as compared to the quarter ended in 2025.

Net Loss is $ 167,295 for the three months ended June 30, 2025 as opposed to a Net Loss of $130,120 for the same period ended 2024. The difference is primarily attributable to the recognition by the Company of a Derivative Loss of $(89,295) in 2025.

Nine months June 30, 2025 comparing with nine months ended June 30, 2024

| Net revenue:                                              |     | (Unaudited)                
 Nine Months Ended June 30, 
 2025                       
 Amount                     |          |   |     | % of    
 Revenue |         |   |     | 2024   
 Amount |          |   |     | % of    
 Revenue |         |   |     | Changes 
 Amount  |          |   |     | % |           |   |
|:----------------------------------------------------------|:----|:---------------------------|---------:|:--|:----|:--------|--------:|:--|:----|:-------|---------:|:--|:----|:--------|--------:|:--|:----|:--------|---------:|:--|:----|:--|----------:|:--|
| Revenues                                                  |     | $                          |